CN115851745B - Application of substance for regulating Esrrb activity in preparation of product for intervening retinal cleavage disease - Google Patents
Application of substance for regulating Esrrb activity in preparation of product for intervening retinal cleavage disease Download PDFInfo
- Publication number
- CN115851745B CN115851745B CN202211281658.5A CN202211281658A CN115851745B CN 115851745 B CN115851745 B CN 115851745B CN 202211281658 A CN202211281658 A CN 202211281658A CN 115851745 B CN115851745 B CN 115851745B
- Authority
- CN
- China
- Prior art keywords
- esrrb
- retinal
- expression
- regulating
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150099612 Esrrb gene Proteins 0.000 title claims abstract description 116
- 230000000694 effects Effects 0.000 title claims abstract description 47
- 238000003776 cleavage reaction Methods 0.000 title claims abstract description 31
- 230000002207 retinal effect Effects 0.000 title claims abstract description 31
- 230000007017 scission Effects 0.000 title claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 19
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 17
- 201000010099 disease Diseases 0.000 title claims abstract description 16
- 239000000126 substance Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000014509 gene expression Effects 0.000 claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 102000010175 Opsin Human genes 0.000 claims description 35
- 108050001704 Opsin Proteins 0.000 claims description 35
- 108020004459 Small interfering RNA Proteins 0.000 claims description 23
- 239000000556 agonist Substances 0.000 claims description 21
- WLKOCYWYAWBGKY-CPNJWEJPSA-N n-[(e)-[4-(diethylamino)phenyl]methylideneamino]-4-hydroxybenzamide Chemical compound C1=CC(N(CC)CC)=CC=C1\C=N\NC(=O)C1=CC=C(O)C=C1 WLKOCYWYAWBGKY-CPNJWEJPSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 101800001318 Capsid protein VP4 Proteins 0.000 claims description 13
- 101150043308 KCNB1 gene Proteins 0.000 claims description 13
- 230000002222 downregulating effect Effects 0.000 claims description 13
- 101100356568 Caenorhabditis elegans rgs-9 gene Proteins 0.000 claims description 12
- 238000011813 knockout mouse model Methods 0.000 claims description 12
- 230000004382 visual function Effects 0.000 claims description 10
- 206010038848 Retinal detachment Diseases 0.000 claims description 8
- 230000004264 retinal detachment Effects 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 5
- 238000003209 gene knockout Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 210000001766 X chromosome Anatomy 0.000 claims description 4
- 230000030279 gene silencing Effects 0.000 claims description 4
- 238000012224 gene deletion Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 27
- 238000011282 treatment Methods 0.000 abstract description 11
- 230000037430 deletion Effects 0.000 abstract description 9
- 238000012217 deletion Methods 0.000 abstract description 9
- 230000001276 controlling effect Effects 0.000 abstract description 8
- 230000004438 eyesight Effects 0.000 abstract description 6
- 230000035772 mutation Effects 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 101150084777 RS1 gene Proteins 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 28
- 239000002924 silencing RNA Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 description 15
- 208000017441 X-linked retinoschisis Diseases 0.000 description 15
- 101100011486 Mus musculus Elf4 gene Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 102000015694 estrogen receptors Human genes 0.000 description 7
- 108010038795 estrogen receptors Proteins 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 206010064571 Gene mutation Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 238000012014 optical coherence tomography Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000007488 abnormal function Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 108090000629 orphan nuclear receptors Proteins 0.000 description 2
- 102000004164 orphan nuclear receptors Human genes 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000001776 parthenogenetic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004281 retinal morphology Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010032363 ERRalpha estrogen-related receptor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851696 Homo sapiens Steroid hormone receptor ERR2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100119135 Mus musculus Esrrb gene Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 101710049544 Retinin Proteins 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 description 1
- 102100036831 Steroid hormone receptor ERR2 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004491 retinal development Effects 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 201000007714 retinoschisis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides application of a substance for regulating and controlling Esrrb activity in preparation of a product for intervening in retinal splitting, and relates to the technical field of biology. The retinal cleavage disease mediated by the substance for regulating the Esrrb activity is mainly retinal cleavage disease caused by the mutation or deletion of the RS1 gene; esrrb can also be used as a target point for regulating and controlling the expression of the vision function protein for non-diagnosis and treatment purposes, and the technical problem of poor treatment effect on the retinal rival disease product caused by the mutation or deletion of the RS1 gene in the prior art is solved.
Description
Technical Field
The invention relates to the field of biotechnology, in particular to application of a substance for regulating and controlling Esrrb activity in preparation of a product for intervening in retinal splitting.
Background
X chromosome linked congenital retinal cleavage disease (X-Linked Retinoschisis, XLRS) is a relatively common early-onset central retinal degenerative disease, the worldwide incidence rate is 1/5000-1/25000, and is one of the most main causes of male adolescent macular degeneration. XLRS primarily involves both eyes and clinical features include progressive central vision loss, foveal cleavage induced radial streaks, peripheral retinal interlayer cleavage, retinal detachment and vitreous hemorrhage. At present, no effective treatment method for XLRS exists, and clinical observation and treatment of complications are still the main treatment method. The gene mutation is the main cause of XLRS, and the pathogenic gene is RS1.RS1 encodes retinal cleavage protein 1 (retinoscisin 1, RS 1) which plays an important role in retinal development and maintenance structure. The mutation of RS1 leads to abnormal functions of RS1 protein, such as synthesis and secretion of RS1, and further leads to abnormal functions of Muller cell fibers, thereby leading to retinal cleavage. Gene therapy is currently the primary treatment for XLRS, but the clinical trial efficacy is not ideal. However, there is currently no other method of alleviation and treatment internationally other than gene therapy. Therefore, how to improve the therapeutic products of XLRS is a current problem to be solved.
In view of this, the present invention has been made.
Disclosure of Invention
The invention is based on the use of the parthenogenic estrogen receptor Esrrb in the preparation of the medicineRS1The invention aims to provide an application of a substance for regulating and controlling Esrrb activity in preparing a product for interfering with retinal split diseases and a method for regulating and controlling expression of opsin for non-diagnostic and therapeutic purposes, which relieves the existing treatment in the prior artRS1The technical problem of poor treatment effect of retinal rival disease products caused by gene mutation or deletion.
In order to solve the technical problems, the invention adopts the following technical scheme:
according to one aspect of the invention there is provided the use of a substance which modulates Esrrb activity in the manufacture of a product for use in the intervention of retinal rivalry; the retinal split diseaseIs thatRS1Retinal cleavage due to gene mutation or deletion.
Preferably, the retinal riving disease is X chromosome linked congenital retinal riving disease;
or, the retinal cleavage disease is a knockout mammalRS1Retinal cleavage after the gene.
Preferably, the mammal comprises a mouse, rat, rabbit, pig, cow, dog, monkey, or human;
preferably, the mammal comprises a mouse.
Preferably, the product for intervening in retinal cleavage is a product for preventing, treating or alleviating retinal cleavage, and the substance that modulates the activity of Esrrb is an Esrrb expression vector or an Esrrb agonist;
preferably, the Esrrb agonist comprises DY131.
Preferably, the Esrrb inhibitor comprises siRNA, shRNA or miRNA;
preferably, the Esrrb inhibitor is an siRNA;
preferably, the nucleotide sequence of the siRNA is as shown in seq_1 or seq_7.
According to another aspect of the invention, there is provided a method of modulating expression of a opsin protein for non-diagnostic and therapeutic purposes, comprising modulating Esrrb activity to effect modulation of the expression level of the opsin protein;
preferably, the opsin protein comprises one or more of Rho, rgs9 and Kcnb 1.
Preferably, the modulating the expression of the opsin protein is up-regulating the expression of the opsin protein, the modulating the Esrrb activity comprises over-expressing the Esrrb protein, or using an Esrrb agonist to increase the Esrrb activity;
preferably, the up-regulating the expression of the opsin protein is up-regulating the expression of the Kcnb1 protein;
preferably, the Esrrb agonist comprises DY131;
preferably, the up-regulating functionally protein is expressed as up-regulatedRS1Knocking out the expression of the visual function protein of the mammal;
preferably, the mammal comprises a mouse, rat, rabbit, pig, cow, dog, monkey, or human;
preferably, the saidRS1The mammal is gene knockout mammalRS1A knockout mouse.
Preferably, said modulating expression of a opsin protein is down-regulating expression of a opsin protein, said modulating Esrrb activity comprising down-regulating expression of Esrrb using an Esrrb inhibitor;
preferably, the downregulating expression of the opsin protein comprises downregulating expression of one or more of Rho, rgs9 and Kcnb 1;
preferably, the Esrrb inhibitor comprises siRNA, shRNA or miRNA;
preferably, the Esrrb inhibitor is an siRNA;
preferably, the nucleotide sequence of the siRNA is as shown in seq_1 or seq_7.
According to another aspect of the invention, the invention also provides an siRNA for silencing Esrrb, the nucleotide sequence of which is shown as seq_1.
According to another aspect of the present invention, there is also provided a product for down-regulating expression of a opsin protein, the product comprising the above siRNA.
Compared with the prior art, the invention has the following beneficial effects:
the parthenogenic estrogen receptor Esrrb (orphan nuclear hormone receptor estrogen-linked receptor beta), also known as Nr3b2, is one of the important members of the estrogen receptor family. Current Esrrb targeted drugs are mainly hormone analogues, used for climacteric and postmenopausal disorders. The parthenogenetic estrogen receptor Esrrb is never applied to an action target point of a therapeutic drug for eye diseases.
The invention finds that Esrrb is related to the expression of opsin proteins. Esrrb in wild-type mouse MEF cells were knocked down, down regulating opsin expression. At the position ofRS1The expression of opsin was also reduced in knockout mice. Overexpression ofRS1The expression of the Esrrb protein and the visual function protein of the gene knockout mice is recovered. To the direction ofRS1Esrrb agonist was administered to the knockout mice and cleavage cavity visualization of the mice was observed by OCTThe results show that the Esrrb activity can be obviously improved by reducing the amountRS1Retinal morphology in knockout mice.
Based on the findings, the application of the substance for regulating and controlling the Esrrb activity in the preparation of the product for intervening in the retinal rivalry disease can be used for preparing the interveningRS1Retinal cleavage caused by gene mutation or deletion provides a new drug target. Meanwhile, the provided method for regulating and controlling the expression of the vision function protein for non-diagnosis and treatment purposes provides an important research means for researching the vision function protein and related mechanisms or pathological conditions thereof.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 shows the immunofluorescence of wild-type mouse MEF cells in example 2;
FIG. 2 is a schematic diagram of example 2Rs1Knocking out the MEF cell immunofluorescence result of the mice;
FIG. 3 is a graph showing the effect of knock-down Esrrb on expression of a functional protein in murine MEF cells in example 2;
FIG. 4 is a graph showing the effect of Esrrb on expression of a functionally active protein in overexpressing mouse MEF cells in example 2;
FIG. 5 is a schematic diagram of example 1Rs1Knocking out the mouse DNA identification result;
FIG. 6 is a diagram of wild type mice and in example 1Rs1Knocking out the expression condition of the Rs1 protein in the retina of the mouse;
FIG. 7 is a schematic diagram of example 3Rs1The retinal morphology of the mice after intraperitoneal injection of the Esrrb agonist was knocked out.
Detailed Description
The technical solutions of the present invention will be clearly and completely described in connection with the embodiments, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Generally, the nomenclature used in connection with the cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein and the techniques thereof are those well known and commonly employed in the art. Unless otherwise indicated, the methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references, as well as laboratory procedures and techniques thereof, are those well known and commonly used in the art.
It should be noted that:
in the present invention, all embodiments and preferred methods of implementation mentioned herein may be combined with each other to form new technical solutions, if not specifically stated; all technical features and preferred features mentioned herein may be combined with each other to form new solutions; the components involved or their preferred components can be combined with one another to form new technical solutions.
The parthenogenic estrogen receptor Esrrb (orphan nuclear hormone receptor estrogen-linked receptor beta), also known as Nr3b2, is one of the important members of the estrogen receptor family. Esrrb is significantly expressed in retinal photoreceptor cells. Overexpression of Esrrb induces NrL lacking rod photoreceptors −/− Both mice and wild-type mice express rod-like specific genes such as rhodopsin Rho, slc24a1, etc. At present, the medicaments taking Esrrb as targets are mainly non-steroidal female hormones, such as diethylstilbestrol, estradiol, tamoxifen and the like. These drugs are mainly used as hormone analogues for climacteric and postmenopausal disorders, and the parthenogenetic estrogen receptor Esrrb has never been applied to the treatment of ocular diseases.
The invention has been found through experiments that,RS1gene knockout mouseRs1Expression of the visual function proteins Rho, rgs9 and Kcnb1 in-KO) MEF cells was reduced, while siRNA was used against wild typeEsrrb in mouse MEF cells was knocked down, and expression of the visual function proteins Rho, rgs9 and Kcnb1 was also reduced, indicating that Esrrb was associated with expression of visual function proteins.
Further, the inventors have achieved by overexpression ofRs1Esrrb protein in KO mouse MEF cells, and it was found that overexpression of Esrrb up-regulates expression of the opsin protein Kcnb1, demonstrated inRS1Overexpression of Esrrb protein in knock-out cell lines, which can restore the effects of the geneRS1Reduced expression of opsin due to deletion of gene.
Further, the inventors are directed toRs1Mice with KO were administered the Esrrb agonist DY131, observed by OCT (ptical coherence tomography optical coherence tomography)Rs1Morphology of KO mice, finding administration of Esrrb agonist DY131Rs1The cleavage cavity of the KO mouse is obviously reduced compared with that of a blank control, and the result proves that the Esrrb activity can be obviously improvedRs1Retinal morphology in KO mice.
Based on the above findings, in some alternatives, there is provided the use of a substance that modulates Esrrb activity in the manufacture of a product for use in the intervention of retinal rivalry disease.
Wherein "an agent that modulates Esrrb activity" refers to an agent that increases or decreases Esrrb activity. Increasing Esrrb activity is optionally achieved by increasing the expression level of endogenous Esrrb or exogenous Esrrb, or alternatively by increasing Esrrb activity of the cell or body itself; the reduction of Esrrb activity is optionally a down-regulation of Esrrb expression in the cell or body, or alternatively a reduction of Esrrb activity of the cell or body itself. Wherein increasing or decreasing Esrrb activity is compared to the non-interfered wild-type Esrrb activity.
"intervening in retinal detachment" includes preventing, treating, or alleviating retinal detachment.
The retinal cleavage disease regulated in the above embodiment isRS1Retinal cleavage due to gene mutation or deletion.RS1Gene mutations include, but are not limited to, point mutations, or deletion, insertion, and cleavage site mutations.RS1The retinal cleavage induced by the gene mutation is optionally X-chromosome Linked congenital retinal cleavage (X-Linked retinin)oschisis, XLRS), or artificially mutatedRS1Gene-induced retinal detachment, such as those obtained by animals by constructing animal models of retinal detachment. Also optionally a knockout mammalRS1Retinal cleavage after the gene. Wherein the mammal comprises a mouse, rat, rabbit, pig, cow, dog, monkey, or human. Experiments prove that the improvement is achievedRS1Gene knockout mouse Esrrb activity is relievedRS1Retinal cleavage in knockout mice, therefore, in at least one embodiment, agents that modulate Esrrb activity can be used to prepare interventionsRS1Products of retinal cleavage in knockout mice.
In some alternative embodiments, the product for intervention in retinal detachment is a product for preventing, treating, or alleviating retinal detachment, and the substance that modulates Esrrb activity is an Esrrb expression vector or an Esrrb agonist. The Esrrb expression vector is transformed into a host, and can express exogenous Esrrb protein in the host, so that the expression of Esrrb is up-regulated, the amount of Esrrb is increased, and the aim of improving the activity of Esrrb in cells or organisms is fulfilled. The Esrrb agonist can enhance the Esrrb activity and promote downstream reaction, thereby achieving the purpose of enhancing the Esrrb activity in cells or organisms. An example of an Esrrb agonist is DY131 (CAS: 95167-41-2), DY131 (GSK 9089) is an ERRβ and ERRγ selective agonist with very low activity towards ERRα, ERα and ERβ.
The expression quantity of the vision function protein is also found to be changed while the intervention of the retina split disease is realized by regulating and controlling the Esrrb activity. Thus in other alternatives, a method of modulating the expression of a opsin protein for non-diagnostic and therapeutic purposes is provided, wherein the opsin protein includes, but is not limited to, one or more of Rho, rgs9 and Kcnb 1. The test shows that the Esrrb activity in the cell or host is changed, and the expression level of the opsin protein is also changed.
In some alternative embodiments, modulating expression of the opsin protein as up-regulating expression of the opsin protein, modulating Esrrb activity comprises over-expressing the Esrrb protein, or using an Esrrb agonist to increase Esrrb activity. The up-regulating expression of the functional protein is preferably up-regulating Kcnb1 proteinExpression, preferably up-regulation of Kcnb1 protein expression by overexpression of Esrrb; if an Esrrb agonist is used to up-regulate expression of the opsin protein, an alternative example of an Esrrb agonist includes DY131. Up-regulating expression of functionally protein is optionally up-regulatingRS1The expression of the opsin protein in a mammal is knocked out, wherein the mammal includes, but is not limited to, mice, rats, rabbits, pigs, cattle, dogs, monkeys or humans.RS1The knockout mammal is preferablyRS1A knockout mouse.
In other alternative embodiments, modulating expression of a opsin protein is down-regulating expression of the opsin protein, and modulating Esrrb activity comprises down-regulating expression of Esrrb using an Esrrb inhibitor, the down-regulating expression of the opsin protein including, but not limited to, down-regulating expression of one or more of Rho, rgs9, and Kcnb 1. Wherein the Esrrb inhibitor includes, but is not limited to, an siRNA, shRNA or miRNA, for example an siRNA with a nucleotide sequence as shown in seq_1 or seq_7. The SiRNA can also optionally be modified in a manner known in the art, for example by adding two thymines at 3' to increase the stability of the siRNA, the sequence of which is shown in seq_7.
The invention also provides the siRNA for silencing Esrrb, and experiments prove that the expression quantity of the functional proteins Rho, rgs9 and Kcnb1 is reduced by using the siRNA for silencing Esrrb. Correspondingly, the invention also provides a product for down-regulating expression of the vision functional protein, which comprises the siRNA.
The technical solution and technical effects of the present invention are further described below in connection with preferred embodiments.
Example 1
ConstructionRs1Knockout mouse
(1) Preparation of sgrnas and Cas9-mRNA:
rs1-gRNA1 sequence GTTAACTGTAAGGCGAGTAAT (5 'to3', seq_2),
rs1-gRNA2 sequence GAGACTCGTGGGCCATACGCC (5 'to3', seq_3).
The DNA fragment of Rs1-sgRNA was amplified by PCR using sgRNA-Vector as a template, and then recovered as a template for in vitro transcription of the sgRNA. And then the sgRNA is subjected to in-vitro transcription, purification and recovery, and split charging and storage are carried out in a refrigerator at-80 ℃ for standby. Linearizing the Cas9 transcription vector, and then carrying out in vitro transcription, purification, recovery, split charging and storage in a refrigerator at-80 ℃ for later use.
(2) Microinjection: cas9-mRNA and Rs1-sgRNA were co-microinjected into C57 mouse embryos, which were transplanted into the oviduct of surrogate recipient mice after injection.
(3) Embryo transfer and F0 mouse identification and propagation: the fertilized eggs after microinjection are returned to the oviduct of the surrogate mother, and the mice are born about 21 days after embryo transplantation, and genotyping is completed about 2 weeks after birth.
（4）Rs1-KO mouse phenotype identification:
Rs1the DNA extracted from the tail of the knockout mouse was cut and purified by PCR to identify homozygotes, the sequence of the PCR primer is shown in Table 1, and the sequence comparison proves that the XLRS model mouse is successfully constructed, as shown in FIG. 5, the Homo (++) representsRs1KO mouse homozygote, heter (+ -) stands forRs1KO mouse heterozygotes, WT representing wild-type mice, primers and fragments of interest used in each group are shown in Table 2. The Rs1 protein (green fluorescence) visible on the retina of a wild mouse is found through Foundation murine sequence alignment and immunofluorescence research, andRs1KO mice retina showed no Rs1 protein expression, as shown in FIG. 6, demonstrating that XLRS model mice were successfully constructed.
TABLE 1
TABLE 2
Example 2
Effect of Esrrb on XLRS cell model
(1) Construction of XLRS disease modelRs1MEF cell line of KO mice
1. Will become pregnant for 13.5 daysRs1Knockout mice (and control mice) were sacrificed by carbon dioxide inhalation and immersed in 75% alcohol. The abdomen was then rubbed with 75% ethanol, the abdomen was cut with a sterilized tool, the uterus was removed and placed in a 10cm petri dish and rinsed with PBS. With scissorsThe embryo membrane was cut, the embryos removed, transferred to a new 10cm dish, and placenta and other maternal tissues removed. The head (eyes and above) was cut off and all viscera were removed, leaving the limbs of the mice. Washed with sterile PBS. Embryoid bodies were placed in separate 10cm plates, embryos were minced, after which 10ml trypsin was added for digestion (trypsin was allowed to cover cells). After more cells are digested and overflowed, the cells are incubated in a cell culture incubator at 37 ℃ for 30-45 minutes, and then an equivalent amount of MEF culture solution (90% DMEM+10% FBS+1% P/S) is added to terminate the digestion. After the supernatant was sucked through a 200 mesh cell sieve by gentle pipetting, cells were harvested by centrifugation at 1000 rpm for 5 minutes. Then, the cells were resuspended, the cell suspension was transferred to a flask, and 10mL MEF medium was added to allow the cells to grow to confluence (3-4 days).
2. Identification of MEF cell lines
MEF cells were seeded in 24-well plates, after cell attachment, the medium was aspirated and washed with PBS, 0.1% triton x-100 was added and permeabilized for 30min at room temperature, and PBS was washed three times. Blocking with 5% BSA blocking solution was performed for 2 hours at room temperature, and the cells were washed with PBS. Vimentin antibody was added and incubated overnight at 4 ℃. The next day fluorescent secondary antibody was added and incubated for 2 hours at room temperature in the dark. Washing with PBS, adding DAPI dye solution, and incubating for 5min in dark place. After washing, the images were observed and photographed by a fluorescence microscope. Wild-type mouse MEF cellsRs1The results of the KO murine MEF cell immunofluorescence are shown in FIGS. 1 and 2.
(2) Esrrb down-regulation may cause reduced expression of opsin proteins
Wild-type mouse MEF (WT-MEF) cells were plated in 6-well plates, 2.5X10 5 Well cells, protein was extracted by transfecting siRNA, 3 μl (10 μm working concentration) of siRNA per well (GGAUGGAGAUUCUCAUCUUtt, seq_7) and 9 μl lipranaimax transfection reagent, and harvesting the cells after 48 h. WB experiments demonstrated that knockdown Esrrb down regulated expression of opsin proteins. Compared to wild-type mouse MEF (WT-MEF) cells,Rs1knockout of MEF cells in miceRs1-KO-MEF) expression of the opsin proteins Rho, rgs9, kcnb1 is reduced. Expression of the opsin Rho, rgs9, kcnb1 was down-regulated by siRNA knockdown of Esrrb in wild-type mouse MEF (WT-MEF) cells, and the results are shown in fig. 3. From FIG. 3, it can be seen thatIt appears that the knockdown Esrrb down regulates the expression of the functionally active protein. Compared to wild-type mouse MEF (WT-MEF) cells,Rs1expression of the opsin Rho, rgs9, kcnb1 proteins in the (Rs 1-KO-MEF) cells of the knockout mice was reduced. Expression of the visual function proteins Rho, rgs9 and Kcnb1 can be down-regulated after the Esrrb is knocked down by siRNA in wild-type mouse MEF (WT-MEF) cells, which indicates that the Esrrb is related to the expression of the visual function proteins, and the down-regulation of the expression of the Esrrb leads to the reduction of the expression quantity of the visual function proteins.
(3) Esrrb up-regulation can save the vision function protein damage caused by RS1 deletion
Will beRs1Knockout of mouse MEFRs1-KO-MEF) cells were plated in 6cm dishes, 8X 10 5 Cells per dish, protein was extracted by transfecting pcDNA3.1-Esrrb plasmid, 6. Mu.g DNA and 20. Mu.l transfection reagent per well, and harvesting cells after 48 h. The results are shown in FIG. 4, and can be seen from FIG. 4 inRs1Knockout of MEF cells in miceRs1-KO-MEF) overexpression of Esrrb up-regulates expression of the opsin protein Kcnb1, WB experiments confirm that overexpression of Esrrb up-regulates expression of the opsin protein Kcnb 1.
Example 3
Esrrb agonist DY131 versus XLRS mouse modelRs1Therapeutic action of KO mice
(1) Treatment of XLRS mice
Will beRs1KO mice are divided into two groups of 10-15 mice each. At the position ofRs1KO mice were given separate injections of PBS and Esrrb agonist DY131 (CAS: 95167-41-2) 1 mg/kg intraperitoneally 7 days after birth, every other day, for two months. Low dose stimulationRs1KO mice activate the Esrrb receptor.
(2) DY131 can improve visual function of XLRS mice
The morphology of Rs1-KO mice was observed by OCT in 15D, 1M, 1.5M, and 2M, respectively, of the Rs1-KO mice injected with Esrrb agonist DY131 intraperitoneally. As shown in FIG. 7, the cleavage cavity of Rs1-KO mice, to which Esrrb agonist DY131 was administered intraperitoneally, was significantly reduced compared to the blank (PBS) for two months, and as a result, it was confirmed that DY 131-treated groups significantly improved the retinal morphology of Rs1-KO mice.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.
Claims (7)
1. Use of a substance that modulates Esrrb activity in the preparation of a product for treating or alleviating retinal detachment; the retinal cleavage disease is thatRS1Retinal cleavage due to gene deletion;
the substance for regulating the activity of the Esrrb is an expression vector for over-expressing the Esrrb or an Esrrb agonist DY131.
2. The use according to claim 1, wherein the retinal cleavage is X-chromosome linked congenital retinal cleavage.
3. The use according to claim 1, wherein the retinal split is a knockout mouseRS1Retinal cleavage after the gene.
4. The use according to claim 3, wherein the substance that modulates Esrrb activity is Esrrb agonist DY131.
5. A method of modulating expression of an opsin protein for non-diagnostic and therapeutic purposes, wherein said modulating is down-regulating expression of one or more of Rho, rgs9 and Kcnb1 by over-expressing an Esrrb protein by an expression vector to up-regulate expression of an opsin protein Kcnb1 or by down-regulating expression of Esrrb by an siRNA shown in SEQ ID No. 7.
6. The method of claim 5, wherein up-regulating the expression of the functional protein Kcnb1 is up-regulatedRS1The visual function protein Kcnb1 of the gene knockout mouse is expressed.
7. siRNA for silencing Esrrb, wherein the nucleotide sequence of the siRNA is shown in SEQ ID NO. 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211281658.5A CN115851745B (en) | 2022-10-19 | 2022-10-19 | Application of substance for regulating Esrrb activity in preparation of product for intervening retinal cleavage disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211281658.5A CN115851745B (en) | 2022-10-19 | 2022-10-19 | Application of substance for regulating Esrrb activity in preparation of product for intervening retinal cleavage disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115851745A CN115851745A (en) | 2023-03-28 |
| CN115851745B true CN115851745B (en) | 2023-10-27 |
Family
ID=85661609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211281658.5A Active CN115851745B (en) | 2022-10-19 | 2022-10-19 | Application of substance for regulating Esrrb activity in preparation of product for intervening retinal cleavage disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115851745B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107287243A (en) * | 2017-06-20 | 2017-10-24 | 温州医科大学 | A kind of humanized's retinoschisis transgene mouse model and its construction method |
| CN112899311A (en) * | 2019-11-19 | 2021-06-04 | 上海朗昇生物科技有限公司 | Construction method and application of RS1-KO mouse model |
| CN114848850A (en) * | 2022-04-28 | 2022-08-05 | 武汉大学 | Application of RS1 gene in preparation of XLRS therapeutic agent and therapeutic agent |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190122232A (en) * | 2017-02-27 | 2019-10-29 | 리제너론 파아마슈티컬스, 인크. | Non-human Animal Model of Retinal Separation |
-
2022
- 2022-10-19 CN CN202211281658.5A patent/CN115851745B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107287243A (en) * | 2017-06-20 | 2017-10-24 | 温州医科大学 | A kind of humanized's retinoschisis transgene mouse model and its construction method |
| CN112899311A (en) * | 2019-11-19 | 2021-06-04 | 上海朗昇生物科技有限公司 | Construction method and application of RS1-KO mouse model |
| CN114848850A (en) * | 2022-04-28 | 2022-08-05 | 武汉大学 | Application of RS1 gene in preparation of XLRS therapeutic agent and therapeutic agent |
Non-Patent Citations (2)
| Title |
|---|
| Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse;T K Park等;《Gene Ther.》;第16卷(第7期);第916-926页 * |
| 遗传性视网膜劈裂症的研究进展;何雪俊等;《遗传性视网膜劈裂症的研究进展》;第44卷(第04期);第515-520页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115851745A (en) | 2023-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Braun et al. | Targeted inactivation of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal death | |
| Kim et al. | Generation of transgenic dogs that conditionally express green fluorescent protein | |
| CN105246490A (en) | Methods of using ZSCAN4 for rejuvenating human cells | |
| JP7341230B2 (en) | IGF-1 gene mutation dwarfism animal model and its production method | |
| CN115851745B (en) | Application of substance for regulating Esrrb activity in preparation of product for intervening retinal cleavage disease | |
| CN110862988B (en) | sgRNA and CREBRF point mutant Bama pig constructed by same and application thereof | |
| KR102005685B1 (en) | Recombinant vector of MERS-CoV expressing fluorescence protein derived from Korean MERS-CoV, and method of preparing the same | |
| CN103215295B (en) | Targeting vector for integrating Lys gene at fixed point of bate-casein locus and cells constructed thereby | |
| CN113166763B (en) | Nucleic acid molecule targeting CYP4V2 gene mutation site and application thereof | |
| EP3185678B1 (en) | Pig model for diabetes | |
| US9259487B2 (en) | Transgenic non-human animal model of neurodegenerative disease | |
| KR102124236B1 (en) | PARK2 knock-out porcine Models for Parkinson' s disease and the Use thereof | |
| CN107937439B (en) | Application of gene and construction method of animal model | |
| US9611304B2 (en) | TNNT1 mini-promoters | |
| CN106062196A (en) | CMP-acetylneuraminic acid hydroxylase targeting vector, vector-transduced transgenic animal for xenotransplantation, and method for producing same | |
| KR20210005074A (en) | How to protect a swine fetus from viral infection | |
| CN115120729B (en) | Application of transmembrane protein41B as drug target in preparation of drug for treating pathological myocardial hypertrophy | |
| CN113648418B (en) | Application of Apelin-APJ inhibitor in preparation of medicine for treating blood testis barrier injury | |
| KR20120079387A (en) | Glucocorticoid responsive transgenic chicken and producing method thereof | |
| US11149284B2 (en) | Transgenic cloned piglet expressing human proinsulin and method of producing the same | |
| RU2778405C2 (en) | Methods for protection of pig fetuses from virus infection | |
| Bano et al. | Introduction to genetic engineering | |
| Edwards et al. | Biological aspects of embryo transfer | |
| Sun et al. | Knockout and Replacement Gene Surgery to Treat Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa | |
| CN103305468A (en) | Anti-virus transgenic mice with highly expressed mouse HDAC6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |